MDS Nordion announces commercial availability of lutetium, rhenium
02 Marzo 2004 - 11:00AM
PR Newswire (US)
MDS Nordion announces commercial availability of lutetium, rhenium
OTTAWA, March 2 /PRNewswire/ -- - Radioisotopes support promising
research and emerging applications in cancer therapy MDS Nordion
today announced the commercial availability of rhenium-186 (Re-186)
and high specific activity lutetium-177 (Lu-177). The availability
of these radioisotopes is in response to growing demand from the
global nuclear medicine community for isotopes used in targeted
radiotherapy research for the development of new cancer therapies.
According to recent market reports, the number of targeted
radiotherapy procedures performed annually in the United States
will grow from less than 5,000 in 2002 to over 200,000 in 2008 as
more radiotherapy products become commercially available. "MDS
Nordion is committed to providing the research community with the
isotopes they require," said Iain Trevena, Senior Vice President,
Nuclear Medicine at MDS Nordion. "The commercial availability of
these isotopes will help the nuclear medicine community pursue
research that may lead to new forms of cancer treatment as well as
allow us to broaden our capabilities in the development of these
promising new therapies." High specific activity isotopes, such as
MDS Nordion's Lu-177, are a favored alternative in certain
applications. "A higher specific activity product is preferred when
radiolabeling peptides, in particular those peptides that are
considered pharmacologically active like Substance P and Bombesin
derivatives,as it will reduce the total peptide mass that needs to
be administered, lowering the incidence of potential side effects
and improving patient welfare," said Professor Helmut R. Maecke, a
leading medical researcher with the Institute of Nuclear Medicine
at University Hospital in Basel, Switzerland. MDS Nordion is
already a key supplier of yttrium-90 (Y-90) and iodine-131 (I-131)
used in the only two radioimmunotherapies currently approved by the
United States Food and Drug Administration. "As with Y-90 and
I-131, we clearly have the capacity to increase production of
Lu-177 and Re-186 as demand grows, and to develop manufacturing
partnerships with pharmaceutical companies as research products
move through clinical trials and into commercial production,"
Trevena said. Lu-177 is being investigated in several studies
around the world. Its relatively long 6.65-day half life allows
more sophisticated procedures to be used to purify and synthesize
the radiopharmaceutical for commercial use, as wellas making Lu-177
easier to combine with biologically active compounds. Lu-177 is a
low-energy beta emitter, providing a tissue-penetration range that
may be more effective for smaller tumors. Re-186 is currently being
used for pain palliation from cancerous metastases in bones and is
being investigated for a range of radiotherapeutic applications.
Both Lu-177 and Re-186 emit gamma radiation that enables diagnostic
imaging of tissue. MDS Nordion's technical, operational and market
expertise means that the nuclear medicine community now has a
dependable and secure source of supply for Lu-177 and Re-186. With
over 50 years of experience, MDS Nordion offers consistent product
quality, flexible product options, responsive customer service and
strongtechnical and scientific expertise. MDS Nordion's global
distribution system ensures quality and timely delivery of
short-lived isotopes. MDS Nordion (http://www.mds.nordion.com/) is
a world leader in radioisotopes, radiation and related
technologies. MDS Nordion is part of MDS Inc. At MDS Inc., our
10,000 highly skilled people provide services, products and
instruments enabling health sciences organizations to enhance the
well being of people around the world. We focus on helping discover
and testnew drugs, assisting doctors to diagnose and treat patients
and preventing the spread of disease. Find out more about MDS Inc.
(TSX: MDS; NYSE: MDZ), at http://www.mdsintl.com/ or by calling
1-888-MDS-7222, 24 hours a day. DATASOURCE: MDS Nordion For further
information: Olivia Nixon, Media Relations, MDS Nordion, Tel: +1
(613) 592-3400 ext. 2832, E-mail: ; Kirsten Gartenburg, inmedia
Public Relations, Tel: +1 (613) 234-7227 ext. 230, E-mail:
Copyright
Grafico Azioni Mds (NYSE:MDZ)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Mds (NYSE:MDZ)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a Mds (Borsa di New York (NYSE)): 0 articoli recenti
Più Mds Articoli Notizie